Innovating to expand boundaries of drug development
As the largest drug development consulting firm in quantitative sciences, Certara continues to gain significant experience and expertise in every specialty practice area, from oncology to rare diseases. In doing so, we have developed in-depth capabilities and knowledge that apply across therapeutic areas, such as complex biologics and pediatrics.
We created practice areas to harness and elevate this expertise to deliver unparalleled support to our partners in pursuit of your goals. The traditional drug development playbook is often not the best path to success in these practice areas. They require out-of-the-box thinking and are the perfect fit for modern, integrated drug development, incorporating not only modeling and simulation but also regulatory science and market access solutions.
Biotechnology
The pace of growth and innovation in biotechnology has been staggering. In our work with thousands of biotechs, we have found that regulatory strategy is as critical as clinical trial design.
From due diligence to clinical pharmacology stewardship and virtual drug development, we offer an integrated suite of customized solutions designed to reach your goals, smarter and faster.
From due diligence to clinical pharmacology stewardship and virtual drug development, we offer an integrated suite of customized solutions designed to reach your goals, smarter and faster.
生物学的製剤
What are complex biologics? They include cell-based therapies, antibody drug conjugates, RNA technologies, multivalent antibodies, immuno-oncology, vaccines, and gene therapies.
Certara supports all phases of development with modeling and simulation, translational modeling, quantitative systems pharmacology, clinical pharmacology, and regulatory submission and strategy.
Certara supports all phases of development with modeling and simulation, translational modeling, quantitative systems pharmacology, clinical pharmacology, and regulatory submission and strategy.
グローバルヘルス
Certara Global Health (CGH) brings together talent, technology, software, and processes to accelerate the development of medicines for those that need them most.
CGH focuses on creating novel and impactful drug development, regulatory science and patient access approaches that deliver effective and affordable therapies to populations in need around the world.
CGH focuses on creating novel and impactful drug development, regulatory science and patient access approaches that deliver effective and affordable therapies to populations in need around the world.
小児
小児は不均質な母集団を構成しています。特に、新生児や幼児は、臓器の発達が薬物曝露および応答に影響を及ぼします。
Certara has unique technology to assess drug performance in all ages. Our experience includes quantitative modeling to determine dosing and safety/ efficacy profile and optimization of formulation and drug labels and developing robust PIPs and PSPs.
Certara has unique technology to assess drug performance in all ages. Our experience includes quantitative modeling to determine dosing and safety/ efficacy profile and optimization of formulation and drug labels and developing robust PIPs and PSPs.
Rare Disease
希少疾患治療薬（オーファンドラッグ）の開発には、臨床・規制・商業面において多様な課題を伴います。患者が少数であるため、臨床試験に向けた被験者の同定および組み入れは非常に困難です。
More Therapeutic Areas
With the largest and most diverse, expert team of its kind, Certara’s 900+ strong team of scientists, regulatory, and market access specialists have worked in virtually all therapeutic areas and modalities, including novel therapies and combination products, across the full range of regulatory pathways
Our proven approach
Drug development of complex biologics takes not only advanced skills but also in-depth understanding of risks and an early roadmap that is agile and robust.
